Join our esteemed faculty in shaping the future of T Cell therapies for relapsed/refractory multiple myeloma (RRMM).
We invite you to participate in an enlightening symposium where our distinguished panel of experts will guide you through the dynamic and rapidly advancing field of T cell-redirecting therapies for RRMM. This is a unique opportunity to gain insightful knowledge as our faculty adeptly translates the latest clinical and real-world data into actionable strategies that can elevate patient care.
Engage directly with our faculty during a dedicated Q&A session, where you can pose questions closely aligned with your clinical practice and gain personalized insights.
We eagerly anticipate your participation in this transformative symposium and look forward to welcoming you!
Click here to find out more about the two symposia hosted by Johnson & Johnson at COMy 2025.
| AGENDA | |
|---|---|
| 09:55-10:00 | Welcome and introduction Mohamad Mohty (France) |
| 10:00-10:30 | Mastering BsAbs in your practice: learnings from the clinical data, RWE and expert opinion Rakesh Popat (UK) |
| 10:30-11:00 | Shifting gears: on the road to optimal CAR-T cell therapy in RRMM Philippe Moreau (France) |
| 11:00-11:20 | Q&A and unlocking the future: what does T cell-redirecting therapy look like in tomorrow’s practice? All faculty |
| 11:20-11:25 | Close and summary Mohamad Mohty (France) |
